High-level soluble expression, purification and characterization of active human midkine from Escherichia coli

W Kelly Yan1, Marjo Goette, Gabriele Hofmann

  • 1Oncology Protein Sciences, Novartis Institutes for BioMedical Research, 4560 Horton Street, Emeryville, CA 94608, USA. kelly.yan@novartis.com

Insights

Researchers successfully produced high-purity recombinant human Midkine (rhMDK), a crucial heparin-binding growth factor for cancer research. This active rhMDK is vital for advancing cancer drug discovery studies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Midkine (MDK) is a heparin-binding growth factor.
  • MDK is highly expressed in various cancers.
  • MDK is a cysteine-rich protein with five disulfide bonds.

Purpose of the Study:

  • To express and purify recombinant human Midkine (rhMDK).
  • To confirm the correct disulfide bond formation and biological activity of rhMDK.
  • To provide a critical reagent for cancer drug discovery.

Main Methods:

  • Recombinant human MDK (rhMDK) expression in Escherichia coli Origami 2 (DE3) strain.
  • Two-step purification using heparin affinity and gel filtration chromatography.
  • Mass spectrometry for disulfide bond analysis and neurite outgrowth assay for activity confirmation.

Main Results:

  • High-level expression of soluble rhMDK achieved.
  • Seven milligrams of high-purity rhMDK obtained from a 3 L culture.
  • Mass spectrometry confirmed correct disulfide bond linkages.
  • Purified rhMDK demonstrated biological activity in a neurite outgrowth assay.

Conclusions:

  • The study successfully produced active, purified rhMDK.
  • The recombinant protein is suitable for use in cancer drug discovery.
  • Active rhMDK is an essential tool for further cancer research.

Related Concept Videos